ALCIPRO

MOA of Ciprofloxacin

• Inhibition of DNA Gyrase

• inhibition of

  topoisomerase -4

• breaking cell wall synthesis

• breaking protein synthesis

There are no bacterial resistance for Alcipro.

• complete blockage of DNA gyrase has no possibility of plasmid mediated resistance.

• fastest bactericidal action does not allow resistance to occur thus even chromosomally mediated resistance is unlikely (chances being 1 in billion).

• synthetic compound, is not susceptible to degradation by any known bacterial enzyme e.g. beta-lactamases

MIC value of Alcipro is

• 0.01-2 mg/ litre

• .01-2 mcg/ml.

• .02-1 mg/litre

• .02-1 mcg/ml.

Alcipro covers following Aerobic Gram-positive Microorganisms

• •Enterococcus faecalis

• •Staphylococcus aureus

• •Staphylococcus epidermidis.

• •Staphylococcus saprophyticus.

• •Streptococcus pneumoniae.

Alcipro Covers Aerobic Gram-negative Microorganisms

• •Citrobacter freundii.

• •Escherichia coli.

• •Haemophiles influenzae.

• •Klebsiella pneumoniae.

• •Moraxella catarrhalis

•Alcipro Covers Aerobic Gram-negative Microorganisms

• •Neisseria gonorrhoeae

• •Pseudomonas aeruginosa

• •Shigella dysenteriae

• •Salmonella typhi

Alcipro does not cross-react with other -------------- such as beta-lactams or aminoglycosides

Match the following PK for Alcipro

• Protein Plasma Binding

• .01-2 Mcg/Ml

• MIC

• 69-85%

• Therapeutic levels

• 4 Hrs

• half -life

• 20-40%

• Bioavailability

• 10-12 hrs

Match the following Dosing for Oral Alcipro

• enteric fever

• 1.5 gms

• Gastroenteritis

• 500mg/ BID

• Maximum Daily dose

• 250 mg/ BID

• gonorrhea

• 500-700 mg

• septicemia/ bacteremia

• 250 mg stat

Match the following Dosages of Alcipro intravenous therapy

• LRTI

• 200mg/ bid

• surgical infections/ prophylaxix

• 100mg, slow IV fusion

• gonorrhea

• 200mg / 100 ml vial

• upper & lower UTI

• 100 mg/ OD